Perspective Therapeutics, Inc.
CATX
$3.90
-$0.03-0.76%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 884.00K | 1.08M | 1.24M | 1.47M | 1.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 884.00K | 1.08M | 1.24M | 1.47M | 1.45M |
| Cost of Revenue | 83.32M | 63.28M | 54.97M | 47.62M | 41.38M |
| Gross Profit | -82.43M | -62.20M | -53.73M | -46.15M | -39.92M |
| SG&A Expenses | 30.23M | 31.53M | 30.77M | 28.58M | 26.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.45M | 95.70M | 86.64M | 77.10M | 68.25M |
| Operating Income | -113.56M | -94.63M | -85.40M | -75.62M | -66.80M |
| Income Before Tax | -104.43M | -108.41M | -97.56M | -86.78M | -80.43M |
| Income Tax Expenses | -793.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -103.64 | -106.31 | -95.47 | -84.68 | -78.33 |
| Earnings from Discontinued Operations | 514.00K | 514.00K | 514.00K | -490.00K | -949.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -103.12M | -105.80M | -94.95M | -85.17M | -79.28M |
| EBIT | -113.56M | -94.63M | -85.40M | -75.62M | -66.80M |
| EBITDA | -110.32M | -91.69M | -82.56M | -72.95M | -64.50M |
| EPS Basic | -1.39 | -1.49 | -1.36 | -1.24 | -1.24 |
| Normalized Basic EPS | -0.88 | -0.72 | -0.64 | -0.56 | -0.55 |
| EPS Diluted | -1.39 | -1.49 | -1.36 | -1.24 | -1.24 |
| Normalized Diluted EPS | -0.88 | -0.72 | -0.64 | -0.56 | -0.55 |
| Average Basic Shares Outstanding | 295.23M | 285.31M | 281.65M | 274.06M | 251.21M |
| Average Diluted Shares Outstanding | 295.23M | 285.31M | 281.65M | 274.06M | 251.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |